Basilea Pharmaceutica AG (0QNA)
London Exchange · UK · prices in GBP · close of 23 Oct 2026
Key indicators
| Last close | GBP 68.85 |
|---|---|
| 52-week range | 44.70 – 70.40 |
| Return, 1 month / 3 months | −0.5% / +32.6% |
| Return, 1 year / 3 years | +41.2% / +87.9% |
| Trend | Uptrend |
| RSI (14) | 58 |
| Volatility (1 year) | 29.0% |
| Worst drawdown (1 year) | -17.5% |
| Average daily value traded | 0.89M GBP |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Basilea Pharmaceutica is a pharmaceutical company based in Basel, Switzerland, that focuses on medicines for serious infections and cancer. It develops and commercialises antibiotics and antifungal treatments used in hospitals, including products for difficult-to-treat bacterial and fungal infections, and it also works on cancer therapies. Its customers are mainly hospitals and healthcare providers, and it works with partners to make its medicines available in markets around the world.
Basilea Pharmaceutica AG trades under the code 0QNA on the London Exchange in UK, with its price quoted in pounds sterling (GBP). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Basilea Pharmaceutica AG (0QNA) trades on the London Exchange in UK. It last closed at GBP 68.85 on 23 October 2026.
Its price-based Market X-Ray is 78 out of 100 (a strong price profile), ranking 108 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 41.2% and over the last three months it rose 32.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 90 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 22.0% | ||
| From 52-week high | -1.5% | ||
| Momentum | 88 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 32.6% | ||
| 6-month return | 27.8% | ||
| 12-month return, skipping the last month | 41.9% | ||
| Stability (higher is calmer) | 72 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 29.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -17.5% | ||
| Liquidity | 52 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.89M GBP | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +4.5% |
|---|---|
| 1 month | −0.5% |
| 3 months | +32.6% |
| 6 months | +27.8% |
| 1 year | +41.2% |
| 3 years | +87.9% |
| 5 years | +58.4% |
Signals
| 50-day / 200-day average | 65.87 / 56.44 |
|---|---|
| Golden / death cross (60 days) | Golden, 44 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.55 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.